ADC Therapeutics SA: Prosight Management, LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Prosight Management, LP amended its Schedule 13G filing on ADC Therapeutics SA, disclosing a change in its passive stake in the clinical-stage antibody-drug conjugate developer. The amendment was filed with the SEC under accession number 0001617201-26-000007. Schedule 13G amendments are typically triggered when an investor's ownership crosses the 5% threshold or when a previously reported position changes materially. The filing signals continued institutional interest in ADC Therapeutics, whose pipeline centers on ADCs for hematologic and solid tumors. Investors will watch for further 13G/13D updates and any accompanying changes in the company's ownership base.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
ADC Therapeutics SA, Prosight Management, LP